Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552222 · ClinicalTrials.gov registry record · Phase 3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,590
- Enrollment target
- 20
- Study locations
NCT05552222 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 1,590 participants, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (193% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT05552222, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,590 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab
- DRUG Talquetamab
Study Locations (20)
California
- UCSF Fresno - Clovis
- City of Hope Duarte - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- Cancer and Blood Specialty Clinic - Los Alamitos
- Valkyrie Clinical Trials - Los Angeles
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- University of Arizona Cancer Center - Tucson
Connecticut
- University of Connecticut - Farmington
- Yale New Haven Hospital - New Haven
Florida
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando - Orlando
- Cleveland Clinic Florida - Weston
Maryland
- Johns Hopkins University School of Medicine JHUSOM - Baltimore
- Center for Cancer and Blood Disorders - Bethesda
Delaware
- ChristianaCare Helen F Graham Cancer Center and Research Institute - Newark
Georgia
- City of Hope Cancer Center - Newnan
Illinois
- University Of Illinois Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,590 participants |
| Start Date | 2022-10-25 |
| Est. Completion | 2033-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05552222
The ClinicalTrials.gov registry entry for NCT05552222 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,590 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 543-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (193% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Teclistamab is the first listed.
NCT05552222 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Arizona, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05552222 about?
NCT05552222 is a clinical study titled "A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma". The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
What is the current status of trial NCT05552222?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,590 participants. The study started on 2022-10-25. Estimated completion is 2033-10-28.
What conditions does trial NCT05552222 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05552222?
The interventions under investigation include: Teclistamab (DRUG), Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT05552222?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552222 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.